|1.||Lambeau, Gérard: 18 articles (06/2015 - 02/2003)|
|2.||Gelb, Michael H: 17 articles (06/2015 - 07/2003)|
|3.||Murakami, Makoto: 15 articles (05/2015 - 10/2003)|
|4.||Mallat, Ziad: 13 articles (10/2015 - 10/2005)|
|5.||Rosenson, Robert S: 10 articles (01/2014 - 02/2009)|
|6.||Fujioka, Daisuke: 9 articles (08/2013 - 06/2008)|
|7.||Tedgui, Alain: 8 articles (10/2015 - 10/2005)|
|8.||De Luca, Daniele: 8 articles (01/2013 - 10/2008)|
|9.||Talmud, Philippa J: 7 articles (11/2015 - 01/2006)|
|10.||Weyant, Michael J: 7 articles (08/2014 - 12/2009)|
08/18/2009 - "PX-18 is a selective sPLA(2) inhibitor effective in reducing tissue damage resulting from myocardial infarction. "
05/01/2011 - "The decrease in myocardial infarct size and content of LTB(4) and TXB(2) after cPLA(2) inhibitor administration was greater in WT mice than in sPLA(2)V(-/-) mice. "
06/01/2009 - "Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction."
06/10/2008 - "Furthermore, administration of a sPLA(2) inhibitor reduced myocardial infarct size and suppressed the cytotoxic activity of sPLA(2)-X(+/+) neutrophils. "
06/10/2008 - "Myocardial infarct size was also significantly reduced in lethally irradiated sPLA(2)-X(+/+) mice reconstituted with sPLA(2)-X(-/-) bone marrow compared with sPLA(2)-X(+/+) bone marrow. "
01/13/2006 - "The present study demonstrates that increased sPLA(2) activity in inflammation in the presence of cells that have lost their membrane phospholipid asymmetry can lead to LPA-mediated endothelial dysfunction and loss of vascular integrity."
11/30/2003 - "In this study, we investigated the expression of several sPLA(2)s in rodent inflammation models. "
04/07/2000 - "A series of HDL metabolic studies were performed in transgenic mice that specifically overexpress human sPLA(2) but have no evidence of local or systemic inflammation. "
08/01/2014 - "Human non-pancreatic secretory phospholipase A2 was reported to be associated with inflammatory diseases and considered as a potential drug target for inflammation and other related disease treatment. "
02/01/2013 - "Secretory phospholipase A2 group IIA (sPLA2-IIA) is an active participant of inflammation. "
01/01/2011 - "Previously, secretory phospholipase A2 (sPLA2) inhibition has been used as an adjunct to conventional rheumatoid arthritis therapy in human clinical trials without significant improvement of arthritic pathology. "
07/01/1996 - "Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. "
01/01/2009 - "Secretory phospholipase A2 (sPLA2) and matrix metalloproteinase (MMP) inhibitors are potent modulators of inflammation with therapeutic potential, but have limited efficacy in rheumatoid arthritis (RA). "
02/01/2005 - "Although group IIA secretory phospholipase A2 (sPLA2-IIA) is known to be abundantly present in the joints of patients with rheumatoid arthritis (RA), expression of other sPLA2s in this disease has remained unknown. "
02/01/2005 - "Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells."
|4.||Prostatic Neoplasms (Prostate Cancer)
07/01/2012 - "Our previous study showed that prostate cancer cells overexpress and secrete secretory phospholipases A2 group IIa (sPLA2-IIa) and plasma sPLA2-IIa was elevated in prostate cancer patients. "
05/01/2008 - "Although lipoxygenase and secretory phospholipase A2 inhibition was also effective for decreasing prostate cancer growth in preclinical studies, to our knowledge these strategies have not yet been used in clinical trials. "
01/01/2013 - "Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer."
01/01/2013 - "Secretory phospholipase A(2) (sPLA(2)) cleave phospholipids at sn-2 ester bonds, releasing lysophospholipids and fatty acids, and are over expressed in several pathologies, including inflammation, arthritis, sepsis and breast and prostate cancers. "
|5.||Asthma (Bronchial Asthma)
01/01/2013 - "This paper illustrates the diverse roles of sPLA2s in the immunopathogenesis of the asthma phenotype and directs attention to developing specific inhibitors of sPLA2-V as a potential new therapy to treat asthma and other allergic disorders."
06/01/2011 - "Conclusions and Clinical Relevance These data indicate that sPLA(2) -IIA and sPLA(2) -X are the major sPLA(2) s in human airways, and suggest a link between the levels of sPLA(2) -X in the airways and several features of asthma."
06/01/2011 - "The majority of sPLA(2) activity in BAL fluid was attributed to either sPLA(2) -IIA or sPLA(2) -X. After 10-fold concentration of BAL fluid, the levels of sPLA(2) -X normalized to total protein were increased in asthma and were associated with lung function, the concentration of induced sputum neutrophils, and prostaglandin E(2) . "
12/01/2007 - "Group X sPLA(2) (sPLA(2)-X) was differentially overexpressed in asthma and localized to airway epithelial cells and bronchial macrophages. "
12/01/2007 - "The sPLA(2)s expressed at the highest levels in airway cells of subjects with asthma were groups X and XIIA. "
|3.||1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
|7.||Phospholipases A2 (Phospholipase A2)
|4.||Neonatal Intensive Care